Navigation Links
CuraGen and TopoTarget Announce New Clinical Results With,Belinostat to be Reported at Upcoming Major Medical Meetings

BRANFORD, Conn., April 19, 2007 /PRNewswire-FirstCall/ -- CuraGen Corporation and TopoTarget A/S announced today that preliminary interim clinical data on intravenous belinostat (PXD101), a histone deacetylase (HDAC) inhibitor being investigated for the treatment of cancer, are expected to be presented at two upcoming major medical meetings.

One oral and one poster presentation discussing interim clinical results with belinostat will be made at the 2007 American Society of Clinical Oncology (ASCO) Annual Meeting, which is being hosted in Chicago, IL, June 2-5, 2007. A poster presentation will also be made at the 2007 Pan Pacific Lymphoma Conference, which is being hosted on the Island of Maui, Hawaii, June 11-15, 2007.

    2007 ASCO Annual Meeting


    -- An oral presentation entitled, "A Phase Ib/II study of PXD101 alone and

       in combination with 5-fluorouracil in patients with advanced solid

       tumors," will be made during the conference's Clinical Science

       Symposium entitled Breaking the Silence of the Genome: HDAC Inhibitors

       on Saturday, June 2nd from 2:45 - 4:15 p.m.


    -- A poster presentation entitled, "A Phase I/II study of the safety and

       anti-cancer activity of IV-administered belinostat (PXD101) plus

       carboplatin (C) or paclitaxel (P), or both in patients with advanced

       solid tumors," will be made during the conference's Developmental

       Therapeutics: Molecular Therapeutics poster session on Sunday, June

       3rd\from 8:00 a.m. - 12:00 p.m.


    2007 Pan Pacific Lymphoma Conference


    -- A poster presentation entitled, "A Phase II Study of Belinostat

       (PXD101) in Patients with Recurrent or Refractory Cutaneous or

       Peripheral T-Cell Lymphoma," will be on display during the conference

       beginning at 7:00 a.m., Monday, June 11th through Friday, June 15th.

Reprints of the poster presentations wi
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. CuraGen Presents Update on Clinical Development Program for Belinostat
2. CuraGen Announces New Preclinical Results with Belinostat and Velafermin to be Presented at AACR Annual Meeting
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
5. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
7. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
8. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
9. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
10. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
11. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
Post Your Comments:
(Date:12/17/2014)... , The new ... of information concerning the biopharmaceutical Group,s national and international clinical ... to the recently launched institutional website that is receiving accolades ... by a new chapter in the fascinating story of Drug ... and panoramic hub on the world of clinical research, ranging ...
(Date:12/17/2014)... Mass. , Dec. 17, 2014  RXi ... biotechnology company focused on discovering, developing and commercializing ... RNA-targeted technologies, today announced completion of enrollment in its ... from the 3-month observations confirmed the 1-month findings ... Logo - http://photos.prnewswire.com/prnh/20130917/NE80755LOGO ...
(Date:12/15/2014)... , December 15, 2014 ... Am 19. und 20. Februar sind alle ... SAFE MEDICINE ECOSYSTEM PARTNER PROGRAMM ™ 2015 ... besuchen. Diese Tagung soll dazu ... Möglichkeit geben, die neue profitablen Unternehmensdienstleistungen, die ...
Breaking Medicine Technology:Dompé Offers a New "Window" on the World of Scientific Research, with the http://www.dompetrials.com Website, Dedicated to Clinical Trials 2Dompé Offers a New "Window" on the World of Scientific Research, with the http://www.dompetrials.com Website, Dedicated to Clinical Trials 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 2RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 4RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 5Symposium über Aegates Ecosystem-Partner-Programm für sichere Medikamente vom 19. - 20. Februar 2015 in Amsterdam 2
(Date:12/19/2014)... (HealthDay News) -- Injectable drug users who also use ... rate of other substance users, a new study finds. ... the risk of suicide attempt and completed suicide," Didier ... said in a university news release. "However, there are ... know who among substance users were actually more likely ...
(Date:12/19/2014)... 19, 2014 (HealthDay News) -- The cost of cancer ... a new study finds. Researchers examined data from ... diagnosed with colorectal or lung cancer. Of those patients, ... and more than 100 had advanced cancer. Nearly ... pay their medical bills, which was linked with a ...
(Date:12/19/2014)... 19, 2014 Surviving Mesothelioma says thousands of ... indicates that these pipes can leach asbestos into drinking water ... full story on the Surviving Mesothelioma website. , ... natural asbestos deposits, decaying water mains made of asbestos cement ... , To protect consumers from mesothelioma , water providers ...
(Date:12/19/2014)... HealthDay Reporter THURSDAY, ... the United States -- along with Angelina Jolie,s chickenpox ... highlighted cracks in the nation,s public health defense against ... released Thursday. Half of U.S. states are poorly ... outbreaks. That was the main conclusion of the report ...
(Date:12/19/2014)... December 19, 2014 B. E. Smith, ... healthcare providers, has been retained to lead a national ... Hospital in Franklin, Ind. The top executive search firm ... placed more than 900 healthcare executives into organizations. ... service hospital providing care to the residents of Johnson ...
Breaking Medicine News(10 mins):Health News:Cocaine, Amphetamines May Up Injection Drug Users' Suicide Risk 2Health News:Cancer Treatment Costs Weigh Heavily on Patients, Study Finds 2Health News:Surviving Mesothelioma Warns of Potential Mesothelioma Risk from Cement Water Pipes 2Health News:Most States Not Ready to Handle Infectious Disease Outbreaks: Report 2Health News:Most States Not Ready to Handle Infectious Disease Outbreaks: Report 3Health News:Most States Not Ready to Handle Infectious Disease Outbreaks: Report 4Health News:Johnson Memorial Hospital Retains B. E. Smith to Recruit New Chief Financial Officer 2Health News:Johnson Memorial Hospital Retains B. E. Smith to Recruit New Chief Financial Officer 3
... Phase II Clinical Trial conducted by a cancer institute in ... kidney cancer with the help of bevacizumab and erlotinib[1], the ... and may help in prolonging patient's survival. ,Renal ... especially once it has started to spread to other sites ...
... vision through cell transplants when they treated animals suffering from ... eye damages similar to that seen in many human eye ... which had lost their sight, leading to hopes that it ... happened when immature retinal stem cells were transplanted into the ...
... The AMA Federal Council has rejected outright Pharmaceutical ... are currently being pushed by some medical groups. ... today that any PBS savings derived from changed ... PBS. ,'Evidence-based prescribing information and other ...
... (ADRA) is making preparations for the annual commemoration of World ... is meant to be observed as the international day of ... ,The theme of ADRA's for 2006 is, "AIDS ... and it encourages people all over the world to realize ...
... of developing pancreatic cancer increases by 90% with the intake of ... 70% higher in people who added sugar to any food or ... who added no sugar. ,In spite of high sugar ... the first time that researchers have shown a direct association between ...
... breast cancer charity went bankrupt after it was apparent ... the cause. // Tony Freeman, 40, the man who ... at the High Court in Glasgow for 18 months ... Consultancy (Solutions RMC), raised money for several cancer charities, ...
Cached Medicine News:Health News:Systemic Pre-Surgical Treatment Can Prolong Survival Of Kidney Cancer Patients 2Health News:Systemic Pre-Surgical Treatment Can Prolong Survival Of Kidney Cancer Patients 3Health News:Cell Transplants Can Even Help In Restoring Vision 2Health News:Commemoration of World AIDS Day 2Health News:Charity swindler jailed over cash fraud 2
... analyzer is an affordable system offering ... reliability and consistency of state-of-the-art instrument-based ... way to obtain dependable urine chemistry ... economy of motion and superior efficiency ...
... device consists of a non-compliant balloon with ... longitudinally on its outer surface. When the ... atherotomes score the plaque, creating initiation sites ... as Atherotomy, allows dilatation of the target ...
... intravascular catheters provide a simple, efficient ... pressures in the heart or cardiovascular ... are ideal for high fidelity pressure ... from 2 to 7 French and ...
... intravascular catheters provide a simple, efficient ... pressures in the heart or cardiovascular ... are ideal for high fidelity pressure ... from 2 to 7 French and ...
Medicine Products: